San Diego-based Orexigen Therapeutics has completed a $30 million Series C private equity financing. The deal was financed by new investors MPM BioEquities and Wasatch Advisors, along with existing investors. The money will be used to support the company's clinical programs for its two lead drug candidates: Contrave, currently in Phase II/III trials, and Excalia, which is in Phase IIb. Orexigen is involved in developing therapies for the treatment of obesity.
- check out Orexigen's press release for more on the financing